triptorelin / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

50 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
triptorelin / Generic mfg.
2020-004780-71: A study using a hormone drug during chemotherapy for fertility protection of young women and teenagers with cancer - ProFertil En studie med ett hormonpreparat som utvärderar effekten av fertilitet hos unga kvinnor och tonåringar med cancer - ProFertil

Not yet recruiting
3
500
Europe
Pamorelin, Powder and solvent for prolonged-release suspension for injection, Pamorelin
Karolinska University Hospital, Karolinska University Hospital
Breast CancerAcute LeukemiaLymphomas (Hodgkin and non-Hodgkin)Sarcomas (Osteo, Soft tissue and Ewing) Bröstcancer, Akut Leukemi, Lymfom (Hodgkin och non-Hodgkin), Sarkom (Ben, Mjukvävnad och Ewing), Breast CancerBlood CancerCancer in lymphnodesCancer in bones Bröstcancer, Blodcancer, Cancer i lymfkörtlar, Cancer i skelett, Diseases [C] - Cancer [C04]
 
 
Co-SOFT, ACTRN12607000542493: Cognitive Function Substudy - A substudy to the SOFT trial (ACTRN12605000416695) which evaluates the cognitive function of premenopausal women with endocrine responsive breast cancer participating in SOFT.

Active, not recruiting
3
357
US, Canada
Tamoxifen, Nolvadex, triptorelin, GnRH analogue, Trelstar Depot, Decapeptyl Depot, Exemestane, Aromasin
Breast Cancer Trials, National Health and Medical Research Council
Cognitive function in pre-menopausal breast cancer patients
12/14
04/16
TEXT, NCT00066703 / 2004-000168-28: Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Active, not recruiting
3
2672
Europe, Canada, US, RoW
exemestane, Aromasin, tamoxifen, Nolvadex, triptorelin, GnRH analogue, Trelstar Depot, Decapeptyl Depot
ETOP IBCSG Partners Foundation, National Cancer Institute (NCI), Breast International Group
Breast Cancer
03/11
12/25
ACTRN12609000532202: Tamoxifen and Exemestane Trial Bone Substudy - A substudy to Amendment 2 of the IBCSG 25-02 / BIG 3-02: Tamoxifen and Exemestane Trial (ACTRN12605000418673) hereby referred to as TEXT-2, which evaluates the effects of exemestane plus Gonadotropin-releasing hormone (GnRH) analogue as adjuvant therapy for premenopausal women with endocrine responsive breast cancer

Active, not recruiting
3
200
 
Breast Cancer Trials, Breast Cancer Trials, International Breast Cancer Study Group (IBCSG)
Effects of adjuvant endocrine therapies on bone mineral density in pre-menopausal breast cancer patients.
 
 
SOFT, NCT00066690: Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Active, not recruiting
3
3066
Europe, Canada, US
Exemestane, Aromasin, FCE-24304, Laboratory Biomarker Analysis, Oophorectomy, Female Castration, Ovariectomy, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RADIATION, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Tamoxifen, Apo-Tamox, Clonoxifen, Dignotamoxi, Ebefen, Emblon, Estroxyn, Fentamox, Gen-Tamoxifen, Genox, ICI 46,474, ICI-46474, Jenoxifen, Kessar, Ledertam, Lesporene, Nolgen, Noltam, Nolvadex, Nolvadex-D, Nourytam, Novo-Tamoxifen, Novofen, Noxitem, Oestrifen, Oncotam, PMS-Tamoxifen, Soltamox, TAM, Tamax, Tamaxin, Tamifen, Tamizam, Tamofen, Tamoxasta, TAMOXIFEN CITRATE, Tamoxifeni Citras, Zemide, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Decapeptyl, Detryptoreline, GnRH analogue, Trelstar Depot, Decapeptyl Depot
ETOP IBCSG Partners Foundation, Breast International Group, Cancer and Leukemia Group B, National Cancer Institute (NCI), NSABP Foundation Inc, NCIC Clinical Trials Group, North Central Cancer Treatment Group, SWOG Cancer Research Network
Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
05/14
12/25
ChiCTR-OPN-15007332: The feasibility of Flexible-Started Ovarian Stimulation in women under in-vitro fertilization

Recruiting
3
150
 
injection hMG+oral MPA+oral CC ;injection triptorelin+injection hMG+oral MPA+oral CC ;injection hMG+oral CC
Shanghai Nineth people's hospital; Shanghai Nineth people's hospital, the Natural Science Foundation of Shanghai
infertility
 
 
2007-000230-39: Protective effect of gonadoliberin analogues on endocrine and reproduction ovarian function during antitumour treatment in young girls and women in fertile period: Project of pharmacological gonadal protection and protection of reproduction functions.

Ongoing
3
40
Europe
Diphereline S.R. 3 MG INJ, DIPHERELINE S.R. 3mg, DIPHERELINE S.R. 3mg
Endocrine Society of Czech Republic
The patient with diagnosis: Hodgkin disease and leukaemia. Patients starting at adolescence (B3 - B4 for breast development accordig Tanner criteria) till 34 years be included.
 
 
2009-017222-39: Ensayo clínico aleatorizado, doble ciego, doble enmascarado, multicéntrico para evaluar la eficacia y seguridad de 5 mg de mifepristona oral comparado con triptorelina IM administrados durante 4 meses en el tratamiento de fibroma uterino

Ongoing
3
74
Europe
mifepristona, -, DECAPEPTYL MENSUAL 3,75 mg, polvo y disolvente para suspensión inyectable, DECAPEPTYL MENSUAL 3,75 mg, polvo y disolvente para suspensión inyectable
Laboratorios Litaphar S.A.
fibroma uterino
 
 
2017-000189-31: Optmization and Safety Testng of a Therapy to Prevent Female Infertlity Caused by Advanced Reproductive Age A Hormon Normalizációs Kezelés optimalizálása és biztonságosságának vizsgálata előrehaladodott anyai korú meddő nőbetegeken

Ongoing
3
17
Europe
Decapeptyl, Dispersion for injection, Decapeptyl
Pannon Reprodukciós Intézet B.1.2, Pannon Reprodukciós Intézet
The therapy is intended to treat infertility that is caused by declining egg quality that occurs with advanced maternal age. The purpose of this pilot trial is to optimize the therapeutic protocol. This will result in standardization of the therapeutic regimen. Once this standardization has been achieved, a statistically powered trial will be performed to test the efficacy of the therapy for increasing the rates of pregnancy and healthy live borns. A terápia célja az, hogy kezelje az idősödő nők romló petesetminőségéből adódó meddőséget. Ennek a vizsgálatnak csupán az a célja, hogy optimalizálja az ehhez szükséges terápiás protokollt. Ennek eredményeképpen kapunk egy standardizált terápiás sémát. Ha ez megvan, egy újabb, nagyobb esetszámon végzett vizsgálat fogja tesztelni a kezelés hatékonyságát meddőségben - a terhességi ráták és élveszületések növekedésével., The therapy is to prevent infertility due to aging of the mother. This trial will optimize the therapy and provide safety assessments. A kezelés célja, hogy az anya kora elenére megőrizze a termékenységet. Ez a vizsgálat optimalizálja a kezeléstés ellenőrzi annak biztonságosságát., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]
 
 
2016-001590-32: Controlled ovarian stimulation with highly purified menotropin in low-responder patients. Estimulación ovárica controlada con menotropina altamente purificada en pacientes bajas respondedoras

Ongoing
3
64
Europe
TESTOSTERONA TRANSDERMICA, TRIPTORELINE ACETATE, ORAL CONTRACEPTIVES, PROGESTERONE, Powder and solution for solution for injection, Transdermal gel, Tablet, Capsule, soft, MENOPUR, TESTOSTERONA TRANSDÉRMICA GEL, TRIPTORELINE ACETATE, ORAL CONTRACEPTIVES, PROGESTERONE
Manuel Macía Cortiñas, FERRING PHARMACEUTICALS
PRIMARY INFERTILITY Esterilidad primaria, INFERTILITY Esterilidad, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
RTOG 0534, NCT00567580: Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Active, not recruiting
3
1792
Canada, US, RoW
PBRT, Prostate bed radiotherapy, Three-Dimensional Conformal Radiation Therapy (3D-CRT), Intensity modulated RT (IMRT), PLNRT, Pelvic lymph node radiotherapy, AA, flutamide, bicalutamide, LHRH agonist, leuprolide, goserelin, buserelin, triptorelin
Radiation Therapy Oncology Group, National Cancer Institute (NCI), Cancer and Leukemia Group B, NRG Oncology
Prostate Cancer
07/18
 
NCT00667069 / 2007-002495-34: Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer

Active, not recruiting
3
424
Europe
triptorelin, Decapeptyl, adjuvant therapy, 3-dimensional conformal radiation therapy
UNICANCER, Ipsen
Prostate Cancer
04/20
04/25
NCT00936390 / 2010-020825-42: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Active, not recruiting
3
1538
Canada, US
bicalutamide, flutamide, anti-androgen therapy, LHRH agonist (antagonist) therapy, leuprolide, goserelin, buserelin, triptorelin, degarelix, Dose-Escalated Radiation Therapy
Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology
Prostate Cancer
10/20
10/25
2020-005754-23: Stereotactic body radiation therapy on Prostate with or without Androgen deprivation therapy, a phase III randomized controlled trial (SPA Trial) RADIOTERAPIA STEREOTASSICA PROSTATICA CON O SENZA TERAPIA DI DEPRIVAZIONE ANDROGENICA, UNO STUDIO RANDOMIZZATO CONTROLLATO DI FASE III (TRIAL SPA)

Not yet recruiting
3
310
Europe
Decapeptyl, casodex, [Decapeptyl], [casodex], Powder and solvent for solution for injection/infusion, Coated tablet, Decapeptyl, CASODEX - 50 MG COMPRESSE RIVESTITE CON FILM 28 COMPRESSE
AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA, IPSEN SPA
prostate acinar adenocarcinoma Pazienti adenocarcinoma acinare prostatico, prostate acinar adenocarcinoma adenocarcinoma acinare della prostata, Diseases [C] - Cancer [C04]
 
 
NCT01546987: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Active, not recruiting
3
239
Canada, US
GnRH agonist, LHRH analog, leuprolide, goserelin, buserelin, triptorelin, Gonadotropin-releasing hormone (GnRH) Agonist, LHRH agonist, Anti-androgen, flutamide, bicalutamide, androgen suppression, TAK-700, Radiation therapy
Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology
Prostate Cancer
11/21
06/29
2022-000066-18: Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial treatment and a maximum of 5 metastasen. Onderzoek naar metastase gerichte therapie al dan niet in combinatie met hormoontherapie bij patiënten met een herval van prostaatkanker na initiële behandeling en maximum 5 metastasen.

Not yet recruiting
3
873
Europe
Implant in pre-filled syringe, Powder and solvent for solution for injection, Powder and solvent for suspension for injection, Capsule, soft, Zoladex 3,6 mg implant, Depo-Eligard 7,5 mg implant, Decapeptyl Sustained Release 11,25 mg, Zoladex Long Acting, 10,8 mg, implantaat, Depo-Eligard 45 mg implant, Depo-Eligard 22,5 mg implant, Decapeptyl Sustained Release 3,75 mg, Decapeptyl Sustained Release 22,5 mg, Xtandi 40 mg soft capsules
Universitaire Ziekenhuizen Leuven, Universitaire Ziekenhuizen Leuven
Oligorecurrent hormone-sensitive prostate cancer patients, Recurrent hormone-sensitive prostate cancer patients with maximum 5 metastasis, Diseases [C] - Cancer [C04]
 
 
2021-006975-41: Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy: a multicentre phase III randomised controlled trial Terapia de deprivación androgénica de corta ó larga duración en combinación con radioterapia de rescate en pacientes con cáncer de próstata con recidiva bioquímica tras cirugía: un ensayo fase III aleatorizado, controlado, multicéntrico

Not yet recruiting
3
534
Europe
triptorelina equivalente, triptorelina (pamoato), leuprorelina, goserelina, Powder and solvent for prolonged-release suspension for injection, Powder and solvent for solution for injection, Powder and solution for solution for injection, Powder and solvent for suspension for injection in pre-filled syringe, Powder and solvent for solution for injection in pre-filled syringe, Implant in pre-filled syringe, Decapeptyl semestral, Decapeptyl trimestral, Eligard mensual, Eligard semestral, Eligard trimestral, Procrin Mensual, Procrin Semestral, Procrin Trimestral, Zoladex
GICOR, GICOR
Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy Terapia de deprivación androgénica de corta ó larga duración en combinación con radioterapia de rescate en pacientes con cáncer de próstata con recidiva bioquímica tras cirugía, prostate cancer cáncer de próstata, Diseases [C] - Cancer [C04]
 
 
NCT04087408: Role of Triptorelin 0.1 mg as a Luteal Phase Support in Assisted Reproductive Technique After Embryo Transfer : a Randomized Controlled Trial

Recruiting
3
150
RoW
Effect of adding gonadotropins releasing hormone agonist to progesterone for luteal phase support in assisted reproductive technique )antagonist cycles(: a randomized controlled trial
Moustafa Mohammed Abouelea
Effect of Adding GnRHa as Luteal Phase Support in Antagonist ART Cycles
07/22
12/22
NCT05029622 / 2022-003857-78: A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.

Completed
3
66
RoW
Triptorelin Pamoate
Ipsen, Ipsen Pharma
Central Precocious Puberty
08/22
02/23
2019-001830-32: Impact of ultra-long versus long down-regulation protocol on IVF/ICSI outcomes in adenomyosis.

Not yet recruiting
3
674
Europe
Decapeptyl, VIVELLEDOT, Powder and solvent for solution for injection, Transdermal patch, Decapeptyl, Vivelledot
University Hospital Toulouse, Programme Hospitalier de Recherche Clinique National 2017
Infertilty in women with adenomyosis., Infertilty in women with adenomyosis., Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
NCT05397795: COMPARING TWO PROTOCOLS FOR FINAL OOCYTE MATURATION IN POOR RESPONDERS UNDERGOING GnRH-ANTAGONIST ICSI CYCLES

Not yet recruiting
3
160
NA
10000 IU hCG (Choriomon5000 IU; IBSA), CHORIONIC GONADOTROPHIN 5000 U, Triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring), TRIPTOFEM 0.1 mg
Alexandria University
Infertility
12/22
01/23
T-TRANSPORT, NCT02418572 / 2014-001835-35: Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial

Terminated
3
290
Europe
Testosterone gel, Androgel 1% 0.55 gr / day, Placebo gel
Institut Universitari Dexeus
Infertility, Poor Ovarian Response
12/23
02/24
URONCOR 06-24, NCT05781217: Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624

Recruiting
3
534
Europe
triptorelin, goserelin, leuprorelin
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence, Androgen Deprivation Therapy, Metastases-free Survival
12/23
12/32
2-Shot, NCT06134479: Comparison of Sequential CFA vs CFA +rFSH for Elective Fertility Preservation.

Recruiting
3
194
Europe
150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5, 150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger
Fundación Santiago Dexeus Font, Organon
Fertility
09/25
01/26
NCT05972902: Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes

Recruiting
3
387
RoW
Dydrogesterone, Duphaston, Cetrorelix acetate, cetrotide, Triptorelin, Decapeptyl, sc 0.1 mg/day
Beni-Suef University
IVF
12/23
12/23
SOLOAGO, NCT06150703: Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles

Not yet recruiting
3
652
Europe
Ovulation induction with hCG + Luteal phase support with vaginal progesterone, Ovulation triggering by Triptorelin + Luteal phase support by Nafarelin
Assistance Publique - Hôpitaux de Paris
In Vitro Fertilization, ICSI Intracytoplasmic Spermatozoid Injection
09/27
09/27
LIBELULA, NCT06129539: A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty

Recruiting
3
53
US
Debio 4326
Debiopharm International SA
Central Precocious Puberty
07/26
09/27
NCT05458856 / 2021-005719-29: Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate

Active, not recruiting
3
147
Europe, RoW
Triptorelin embonate 22.5 mg, Decapeptyl
Ipsen
Prostate Cancer
07/24
07/24
NCT05590793: Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

Active, not recruiting
3
195
RoW
Triptorelin pamoate (embonate) salt, Dipherelin
Ipsen
Advanced Prostate Cancer, Metastatic Prostate Cancer, Locally Advanced Prostate Cancer
10/24
10/24
NCT04064840: GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET

Recruiting
3
784
RoW
IVF: Decapeptyl and hCG, IVF: hCG, FET: Decapeptyl, FET: normal saline, IVF: hCG and normal saline, FET: Normal Saline
The University of Hong Kong
Subfertility
09/24
12/24
HOBOE, NCT00412022: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.

Active, not recruiting
3
1294
Europe
tamoxifen, triptorelin, letrozole, zoledronic acid
National Cancer Institute, Naples, University of Campania "Luigi Vanvitelli"
Breast Cancer
11/24
11/24
NCT01492972: Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

Recruiting
3
192
US
Radiation, Androgen Suppression Therapy, leuprolide, goserelin, buserelin, or triptorelin
Proton Collaborative Group
Prostate Cancer
12/25
 
SPA, NCT05019846: SRT Versus SRT+ADT in Prostate Cancer

Recruiting
3
310
Europe
Triptorelin Embonate, Bicalutamide 50 mg
Marco Lorenzo Bonu, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Prostate Cancer
12/25
12/29
SPARKLE, NCT05352178: Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

Recruiting
3
873
Europe
Radiotherapy (SBRT) and/or surgery (metastasectomy), Androgen deprivation therapy, Androgen receptor targeted therapy
Universitaire Ziekenhuizen Leuven
Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic, Metastatic Cancer, Oligometastatic Disease, Oligometastasis, Hormone Sensitive Prostate Cancer
04/27
04/32
ProFertil, NCT05328258: Use of GnRHa During Chemotherapy for Fertility Protection

Recruiting
3
500
Europe
Triptorelin Embonate, Pamorelin, Sodium Chloride solution 0.9%, Placebo
Kenny Rodriguez-Wallberg
Breast Cancer Female, Acute Leukemia, Lymphoma, Osteosarcoma, Soft Tissue Sarcoma, Ewing Sarcoma
01/28
01/32
S1802, NCT03678025: Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Recruiting
3
1273
Europe, US, RoW
Abiraterone, CB 7598, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Degarelix, FE200486, Firmagon, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, SCH 13521, Tafenil, Tecnoflut, Testotard, Goserelin Acetate, ZDX, Zoladex, Histrelin Acetate, Supprelin, Vantas, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Nilutamide, Anandron, Nilandron, RU-23908, Orchiectomy, Castration, Male Castration, Male Gonadectomy, orchidectomy, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation, Radical Prostatectomy, Prostatovesiculectomy, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Decapeptyl, Detryptoreline
SWOG Cancer Research Network, National Cancer Institute (NCI)
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
04/28
10/31
ERADICATE, NCT04484818: Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The Study

Active, not recruiting
3
27
US
Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, ODM 201, ODM-201, Goserelin Acetate, ZDX, Zoladex, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Prostate Carcinoma
05/28
05/28
CARLHA-2, NCT04181203: Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy

Recruiting
3
490
Europe
Apalutamide, ARN-509, Salvage radiotherapy (SRT), Luteinising Hormone Releasing Hormone agonist (LHRHa), leuprolide, goserelin, triptorelin acetate
UNICANCER, Janssen Pharmaceutica
Prostate Cancer
09/28
12/33
PRIMORDIUM, NCT04557059 / 2019-002957-46: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

Recruiting
3
412
Europe, US, RoW
Radiotherapy, LHRHa, Apalutamide, JNJ-56021927
Janssen Pharmaceutica N.V., Belgium
Prostatic Neoplasms
08/29
08/29
NCT02140190 / 2004-000166-13: Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Active, not recruiting
3
3066
US, Canada
tamoxifen citrate, Nolvadex, TAM, tamoxifen, TMX, exemestane, Aromasin, FCE-24304, PNU 155971, oophorectomy, ovariectomy, radiation therapy, irradiation, radiotherapy, therapy, radiation, triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, D-TRP-6-LHRH, Decapeptyl, TRIP, quality-of-life assessment, quality of life assessment, laboratory biomarker analysis
National Cancer Institute (NCI), Southwest Oncology Group, North Central Cancer Treatment Group, Cancer and Leukemia Group B, National Surgical Adjuvant Breast and Bowel Project (NSABP), Breast International Group, NCIC Clinical Trials Group
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
12/31
 
OFSET, NCT05879926: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting
3
3960
US
Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression
NRG Oncology, National Cancer Institute (NCI)
Breast Cancer
01/32
07/34
GUIDANCE, NCT05050084: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

Recruiting
3
2050
Canada, US
Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, TAK 385, TAK-385, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma
04/32
04/37
INDICATE, NCT04423211: Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Recruiting
3
804
US
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D Conformal, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D radiotherapy, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Radiation, 3D Conformal, Three dimensional external beam radiation therapy (procedure), Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Degarelix, FE200486, Firmagon, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, Fluciclovine F18, (18F)Fluciclovine, (18F)GE-148, 18F-Fluciclovine, [18F]FACBC, Anti-(18f)FABC, Anti-1-Amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid, Anti-[18F] FACBC, Axumin, Fluciclovine (18F), FLUCICLOVINE F-18, GE-148 (18F), GE-148 F-18, Goserelin Acetate, ZDX, Zoladex, Intensity-Modulated Proton Therapy, IMPT, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, TAK 385, TAK-385, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline, Volume Modulated Arc Therapy, VMAT, Volumetric Modulated Arc Therapy (procedure)
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
12/32
12/32
PREDICT-RT, NCT04513717: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The Trial

Recruiting
3
2478
Canada, US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
12/33
12/33
NCT04753177: The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

Active, not recruiting
2/3
120
RoW
Ribocyclib, fulvestrant, triptorelin, Doxorubicin, cyclophosphamide, paclitaxel
Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary
The Neoadjuvant Therapy
01/23
01/24
THUNDER, NCT06282588: Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

Recruiting
2/3
493
Europe
Darolutamide, Nubeqa, BAY1841788, Darolutamide matched placebo, BAY1841788 matched placebo, Radiotherapy, Zoladex 3.6Mg Implant, Goserelin acetate 3.6 mg, Zoladex LA, Goserelin acetate 10.8 mg, Decapeptyl sustained release 22.5 mg, Triptorelin 11.25 mg, Decapeptyl sustained release 11.25 mg, Depo-Eligard 45 mg, Leuprorelin acetate 45 mg, Depo-Eligard 22.5 mg, Leuprorelin acetate 22.5 mg, Depo-Eligard 7.5 mg, Leuprorelin acetate 7.5 mg, Firmagon 120 MG Injection, Degarelix 40 mg, Firmagon 80 MG Injection, Degarelix 20 mg, Docetaxel, Taxotere
Cancer Research Antwerp, Bayer, Veracyte, Inc.
Prostate Cancer
07/30
12/30
LOBSTER, NCT04242017: Long-term Better Than Short-term ADT With Salvage RT

Recruiting
2/3
394
Europe
Triptoreline
Universitaire Ziekenhuizen KU Leuven, Ipsen
Prostate Cancer
02/26
02/31
NCT02685397: Management of Castration-Resistant Prostate Cancer With Oligometastases

Recruiting
2/3
130
Canada
Leuprolide Acetate, Eligard, Lupron, Goserelin Acetate, ZOLADEX, Triptorelin, Trelstar, Enzalutamide, Xtandi, Stereotactic Body Radiation Therapy, SBRT
Sir Mortimer B. Davis - Jewish General Hospital
Castration-resistant Prostate Cancer Patients With Oligometastases
04/25
08/41
DECATEC, NCT04356664: Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis

Recruiting
2/3
180
Europe
GnRH agonist, Decapeptyl 3 mg
Hopital Foch
Endometriosis, Adenomyosis, Infertility, Female
06/25
06/25
VA STARPORT, NCT04787744: Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Recruiting
2/3
464
US
PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease, Goserelin, Histrelin, Leuprolide & Triptorelin, ADT + Nilutamide, Flutamide, & Bicalutamide, Degarelix & Relugolix, ADT + Docetaxel +/- prednisone, ADT + Abiraterone + Prednisone, ADT + Abiraterone + Methylprednisolone, ADT + Apalutamide, ADT + Enzalutamide, Prostate-directed Radiation for De novo oligometastatic prostate cancer
VA Office of Research and Development
Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
07/25
12/25

Download Options